LancetRCT
Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD)
final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.
ConclusionOver the 16-week induction period, rezpegaldesleukin treatment resulted in significant and clinically meaningful improvements across multiple clinical endpoints, including the primary endpoint of EASI percentage change from baseline, in comparison with placebo. Rezpegaldesleukin had a clinically favourable adverse event profile in adult patients with moderate-to-severe atopic dermatitis, supporting its further development as a novel Treg-enhancing biological treatment.
Silverberg JI, Rosmarin D, … senior author Warren RBThe Lancet